+25.2%
ABNB vs GSK
+71.0%
-45.9%
-62.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +0.1% | -0.1% | 0.0% |
| 7D | +6.5% | +0.5% | +6.0% | +6.4% |
| 30D | +9.4% | +9.4% | -0.1% | +8.7% |
| 3M | +0.6% | +1.6% | -1.0% | +0.5% |
| 6M | +33.7% | +1.3% | +32.4% | +33.6% |
| YTD | +33.5% | +6.0% | +27.5% | +33.1% |
| 1Y | +48.8% | +9.1% | +39.8% | +48.2% |
| 3Y | +53.3% | +65.4% | -12.1% | +48.4% |
| 5Y | -12.3% | +43.0% | -55.3% | -15.2% |
| All | +25.2% | +71.0% | -45.9% | +36.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling